Generation of monoclonal antibodies

Ended Purchase Order Awarded Last action

Contract number
HT942523P0030
Awardee
Awarding agency
Obligated
$84,721

Award facts

Contract value 100% obligated
$84,720.53 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Set-aside
Total Small Business
Competition
Competed under SAP · 2 offers Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
North River, ND 58102, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00001 $1,025
Original award $83,696

About this award

The Defense Health Agency awarded a $84,720.53 firm fixed price purchase order to Genovac Antibody Discovery LLC, a small disadvantaged business, for the generation of monoclonal antibodies targeting ferret immunoglobulin M and immunoglobulin G. This requirement was solicited as a 100% small business set-aside. The contract has an ultimate completion date of December 29, 2023 and was awarded on May 1, 2023. The contract was issued under a federal contract opportunity posted on April 7, 2023 with a due date of April 18, 2023. This requirement supports the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

Quick answers

Who was awarded contract HT942523P0030?

HT942523P0030 was awarded to Genovac Antibody Discovery LLC by Defense Health Agency (Department of Defense) on May 1, 2023.

How much is contract HT942523P0030 worth?

The government has obligated $84,721 on HT942523P0030.

Was contract HT942523P0030 competed?

The extent of competition for HT942523P0030 was competed under sap. The government received 2 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award